Business Wire

REPLY: Logistics Reply Optimises Delivery Times for More Nutrition and ESN with LEA Reply

27.2.2025 11:00:00 EET | Business Wire | Press release

Share

Logistics Reply, a leading provider of digital supply chain solutions, has implemented its LEA Reply warehouse management system (WMS) for The Quality Group (TQG) – which owns the ESN and More Nutrition brands. The solution is enhancing logistics operations for the nutritional supplements and sports nutrition manufacturer by optimising stock management and order fulfilment, and ensuring significantly faster direct-to-consumer deliveries – even during peak periods such as Black Week.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250227502858/en/

The Quality Group relies on Logistics Reply's LEA Reply warehouse management system to expand its supply chain processes in the long term. The introduction of LEA Reply not only simplifies and accelerates internal processes at TQG, but also leads to measurable results, which customers can experience with every order. (Photo: Business Wire)

The LEA Reply WMS combines cloud-native architecture with artificial intelligence to allow TQG to seamlessly connect all five warehouses, enhances order fulfillment through multi-order picking, and dynamically prioritises orders in real time. This ensures extremely fast order processing – a crucial advantage given TQG's rapid growth, driven in part by strategic social media marketing. With the new WMS, the company currently processes up to 55,000 orders per day, achieving a 99.9 percent on-time delivery rate and nearly 20 percent faster delivery times.

"Thanks to LEA Reply, we have significantly reduced our lead times within just seven weeks," said Gerit Offenhauser, Vice President Logistics at TQG. "Moreover, the solution’s high scalability enables us to adapt flexibly to market changes and growing order volumes. As a result, we are well prepared for further growth."

The successful implementation at TQG confirms the performance of LEA Reply, which is already in use across various industries. In particular, the integrated multi-agent AI platform provides many companies with decisive advantages: GaliLEA optimises workflows through automated processes and data-driven decisions. With an intuitive user interface and voice control, LEA Reply offers high scalability and flexibility to meet the growing demands of logistics. These innovations have already earned industry recognition: Gartner's Magic Quadrant for Warehouse Management Systems has recognised Reply as a Visionary for the fifth consecutive year.

Reply
Reply [EXM, STAR: REY, ISIN: IT0005282865] specialises in designing and implementing solutions based on new communication channels and digital media. Structured as a network of highly specialised companies, Reply supports leading European industrial groups in sectors such as Telco & Media, Industry and Services, Banking and Insurance, and Public Administration, helping define and develop business models enabled by new paradigms such as AI, Cloud Computing, Digital Media, and the Internet of Things. Reply’s services include Consulting, System Integration, and Digital Services. www.reply.com

Logistics Reply
Logistics Reply provides cutting-edge software solutions that help companies achieve an efficient and more connected digital supply chain where different systems, partners, humans and machines seamlessly interact embracing the use of next-generation technologies such as AI, robotics, wearables and IoT. Logistics Reply accompanies its customers in this transformation journey ensuring rapid time-to-value and long-term quality results thanks to over 20 years of experience and deep knowledge of technologies and supply chain processes. www.lea.reply.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250227502858/en/

Contacts

Media :

Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +39 0117711594

Sandra Dennhardt
s.dennhardt@reply.com
Tel. +49 170 4546229

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye